- Home
- HLP vs MGNX Comparison
HLP vs MGNX Comparison
Compare HLP & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLP
- MGNX
- Stock Information
- Founded
- HLP 2021
- MGNX 2000
- Country
- HLP China
- MGNX United States
- Employees
- HLP N/A
- MGNX N/A
- Industry
- HLP Industrial Machinery/Components
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- HLP Industrials
- MGNX Health Care
- Exchange
- HLP Nasdaq
- MGNX Nasdaq
- Market Cap
- HLP 102.1M
- MGNX 99.7M
- IPO Year
- HLP 2023
- MGNX 2013
- Fundamental
- Price
- HLP $1.34
- MGNX $1.84
- Analyst Decision
- HLP
- MGNX Hold
- Analyst Count
- HLP 0
- MGNX 6
- Target Price
- HLP N/A
- MGNX $3.20
- AVG Volume (30 Days)
- HLP 301.9K
- MGNX 734.1K
- Earning Date
- HLP 05-15-2026
- MGNX 11-04-2025
- Dividend Yield
- HLP N/A
- MGNX N/A
- EPS Growth
- HLP N/A
- MGNX N/A
- EPS
- HLP 0.02
- MGNX N/A
- Revenue
- HLP $16,731,357.00
- MGNX $165,495,000.00
- Revenue This Year
- HLP N/A
- MGNX N/A
- Revenue Next Year
- HLP N/A
- MGNX N/A
- P/E Ratio
- HLP $63.94
- MGNX N/A
- Revenue Growth
- HLP 19.13
- MGNX 303.47
- 52 Week Low
- HLP $0.61
- MGNX $0.99
- 52 Week High
- HLP $1.82
- MGNX $5.10
- Technical
- Relative Strength Index (RSI)
- HLP 52.11
- MGNX 55.97
- Support Level
- HLP $1.40
- MGNX $1.64
- Resistance Level
- HLP $1.54
- MGNX $2.15
- Average True Range (ATR)
- HLP 0.15
- MGNX 0.13
- MACD
- HLP -0.04
- MGNX 0.02
- Stochastic Oscillator
- HLP 10.26
- MGNX 48.31
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.